Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5221_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
21 Мб
Скачать
 Infectious Disease and Neurocognition
HELMER, C., PASQUIER, F. & DARTIGUES, J. F. 2006. [Epidemiology of Alzheimer disease and re-
lated disorders]. Med Sci (Paris), 22, 288– 296. HIRAI, Y., HAQUE, M., YOSHIDA, T., YOKOTA, K., YASUDA, T. & OGUMA, K. 1995. Unique
cholesteryl glucosides in Helicobacter pylori: Composition and structural analysis. J Bacteriol, 177,
5327– 5333. HONJO, K., VAN REEKUM, R. & VERHOEFF, N. P. 2009. Alzheimer’s disease and infection: Do in-
fectious agents contribute to progression of Alzheimer’s disease? Alzheimers Dement, 5, 348– 360. HUANG, W. S., YANG, T. Y., SHEN, W. C., LIN, C. L., LIN, M. C. & KAO, C. H. 2014. Association be-
tween Helicobacter pylori infection and dementia. J Clin Neurosci, 21, 1355– 1358. JARUVONGVANICH, V., SANGUANKEO, A., JARUVONGVANICH, S. & UPALA, S. 2016.
Association between Helicobacter pylori infection and multiple sclerosis: A systematic review and
meta- analysis. Mult Scler Relat Disord, 7, 92– 97. KATE, V., ANANTHAKRISHNAN, N. & TOVEY, F. I. 2013. Is Helicobacter pylori infection the pri-
mary cause of duodenal ulceration or a secondary factor? A review of the evidence. Gastroenterol Res
Pract, 2013, 425840. KAYALI, S., MANFREDI, M., GAIANI, F., BIANCHI, L., BIZZARRI, B., LEANDRO, G., DI MARIO,
F. & DE’ ANGELIS, G. L. 2018. Helicobacter pylori, transmission routes and recurrence of infec-
tion: State of the art. Acta Biomed, 89, 72– 76. KESSLER R. C., BERGLUND P., DEMLER O., JIN R., MERIKANGAS K. R., WALTERS E. E., Lifetime
prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey
Replication [published correction appears in Arch Gen Psychiatry. 2005 Jul;62(7):768. Merikangas,
Kathleen R [added]]. Arch Gen Psychiatry. 2005;62(6):593-602. doi:10.1001/archpsyc.62.6.593. KESSLER R. C., MCGONAGLE K. A., ZHAO S., et al. Lifetime and 12-month prevalence of DSM-III-R
psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen
Psychiatry. 1994;51(1):8–19. KIANI, S., VAKILIAN, A., KAMIAB, Z. & SHAMSIZADEH, A. 2020. Correlation of dietary intake and
Helicobacter pylori infection with multiple sclerosis, a case- control study in Rafsanjan, Iran, 2017–
18. Qatar Med J, 2020, 45.
KIRA, J. 2015. Helicobacter pylori infection might prove the hygiene hypothesis in multiple sclerosis. J
Neurol Neurosurg Psychiatry, 86, 591– 592. KOUNTOURAS, J., BOZIKI, M., GAVALAS, E., ZAVOS, C., DERETZI, G., CHATZIGEORGIOU, S.,
KATSINELOS, P., GRIGORIADIS, N., GIARTZA- TAXIDOU, E. & VENIZELOS, I. 2010. Five- year
survival aer Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol, 23,
199– 204. KOUNTOURAS, J., BOZIKI, M., GAVALAS, E., ZAVOS, C., DERETZI, G., GRIGORIADIS,
N., TSOLAKI, M., CHATZOPOULOS, D., KATSINELOS, P., TZILVES, D., ZABOURI, A. &
MICHAILIDOU, I. 2009a. Increased cerebrospinal uid Helicobacter pylori antibody in Alzheimer’s
disease. Int J Neurosci, 119, 765– 777. KOUNTOURAS, J., BOZIKI, M., GAVALAS, E., ZAVOS, C., GRIGORIADIS, N., DERETZI, G.,
TZILVES, D., KATSINELOS, P., TSOLAKI, M., CHATZOPOULOS, D. & VENIZELOS, I. 2009b.
Eradication of Helicobacter pylori may be benecial in the management of Alzheimer’s disease. J
Neurol, 256, 758– 767. KOUNTOURAS, J., GAVALAS, E., BOZIKI, M. & ZAVOS, C. 2007a. Helicobacter pylori may be in-
volved in cognitive impairment and dementia development through induction of atrophic gastritis,
vitamin B- 12 folate deciency, and hyperhomocysteinemia sequence. Am J Clin Nutr, 86, 805– 806. KOUNTOURAS, J., GAVALAS, E., ZAVOS, C., STERGIOPOULOS, C., CHATZOPOULOS, D.,
KAPETANAKIS, N. & GISAKIS, D. 2007b. Alzheimer’s disease and Helicobacter pylori infec-
tion: Defective immune regulation and apoptosis as proposed common links. Med Hypotheses, 68,
378– 388. KOUNTOURAS, J., PAPAEFTHYMIOU, A., GAVALAS, E., POLYZOS, S. A., BOZIKI, M.,
KYRIAKOU, P., KATSINELOS, P., ZAVOS, C., LIATSOS, C., TZIVRAS, D., TZITIRIDOU-
CHATZOPOULOU, M., DARDIOTIS, E., DERETZI, G., VARDAKA, E. & DOULBERIS, M. 2020.
Helicobacter pylori infection as a potential risk factor for multiple sclerosis. Med Hypotheses, 143,
110135.
Helicobacter pylori 159
KOUNTOURAS, J., TSOLAKI, M., BOZIKI, M., GAVALAS, E., ZAVOS, C., STERGIOPOULOS,
C., KAPETANAKIS, N., CHATZOPOULOS, D. & VENIZELOS, I. 2007c. Association between Helicobacter pylori infection and mild cognitive impairment. Eur J Neurol, 14, 976– 982.
KOUNTOURAS, J., TSOLAKI, M., GAVALAS, E., BOZIKI, M., ZAVOS, C., KARATZOGLOU, P.,
CHATZOPOULOS, D. & VENIZELOS, I. 2006. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology, 66, 938– 940.
KOUNTOURAS, J., ZAVOS, C., GAVALAS, E., BOZIKI, M. & KATSINELOS, P. 2008. Helicobacter
pylori may hold a variable role in multiple sclerosis based on ethnicity. Med Hypotheses, 71, 614– 615.
LACY, B. E. & ROSEMORE, J. 2001. Helicobacter pylori: Ulcers and more: e beginning of an era. J
Nu tr, 131, 2789S– 2793S.
LANGER- GOULD, A. M., GONZALES, E. G., SMITH, J. B., LI, B. H. & NELSON, L. M. 2022. Racial
and ethnic disparities in multiple sclerosis prevalence. Neurology, 98, e1818– e1827.
LEVITT, M., SPECTOR, S., SJOERDSMA, A. & UDENFRIEND, S. 1965. Elucidation of the rate-
limiting step in norepinephrine biosynthesis in the perfused guinea- pig heart. J Pharmacol Exp er, 148, 1– 8.
LINDEBOOM, J. & WEINSTEIN, H. 2004. Neuropsychology of cognitive ageing, minimal cognitive
impairment, Alzheimer’s disease, and vascular cognitive impairment. Eur J Pharmacol, 490, 83– 86.
LIU, N. Y., SUN, J. H., JIANG, X. F. & LI, H. 2021. Helicobacter pylori infection and risk for developing
dementia: An evidence- based meta- analysis of case- control and cohort studies. Aging (Albany NY), 13, 22571– 22587.
LIVINGSTON, G., HUNTLEY, J., SOMMERLAD, A., AMES, D., BALLARD, C., BANERJEE, S.,
BRAYNE, C., BURNS, A., COHEN- MANSFIELD, J., COOPER, C., COSTAFREDA, S. G., DIAS, A., FOX, N., GITLIN, L. N., HOWARD, R., KALES, H. C., KIVIMAKI, M., LARSON, E. B., OGUNNIYI, A., ORGETA, V., RITCHIE, K., ROCKWOOD, K., SAMPSON, E. L., SAMUS, Q., SCHNEIDER, L. S., SELBAEK, G., TERI, L. & MUKADAM, N. 2020. Dementia prevention, inter­vention, and care: 2020 report of the Lancet Commission. Lancet, 396, 413– 446.
MALAGUARNERA, M., BELLA, R., ALAGONA, G., FERRI, R., CARNEMOLLA, A. & PENNISI, G.
2004. Helicobacter pylori and Alzheimer’s disease: A possible link. Eur J Intern Med, 15, 381– 386.
MARSHALL, B. J. & WARREN, J. R. 1984. Unidentied curved bacilli in the stomach of patients with
gastritis and peptic ulceration. Lancet, 1, 1311– 1135.
MARTINEZ- RAMIREZ, D., GIUGNI, J. C., ALMEIDA, L., WALZ, R., AHMED, B., CHAI, F. A.,
RUNDLE- GONZALEZ, V., BONA, A. R., MONARI, E., WAGLE SHUKLA, A., HESS, C. W., HASS, C. J. & OKUN, M. S. 2016. Association between antidepressants and falls in Parkinson’s disease. J Neurol, 263, 76– 82.
MEEUS, B., VERSTRAETEN, A., CROSIERS, D., ENGELBORGHS, S., VAN DEN BROECK, M.,
MATTHEIJSSENS, M., PEETERS, K., CORSMIT, E., ELINCK, E., PICKUT, B., VANDENBERGHE, R., CRAS, P., DE DEYN, P. P., VAN BROECKHOVEN, C. & THEUNS, J. 2012. DLB and PDD: A role for mutations in dementia and Parkinson disease genes? Neurobiol Aging, 33, 629 e5– 629.e18.
MENG, L., SHEN, L. & JI, H. F. 2019. Impact of infection on risk of Parkinson’s disease: A quantitative
assessment of case- control and cohort studies. J Neurovirol, 25, 221– 228.
MORAN, A. P. & PRENDERGAST, M. M. 2001. Molecular mimicry in Campylobacter jejuni and
Helicobacter pylori lipopolysaccharides: Contribution of gastrointestinal infections to autoimmu­nity. J Autoimmun, 16, 241– 256.
NAGGA, K., RAJANI, R., MARDH, E., BORCH, K., MARDH, S. & MARCUSSON, J. 2003. Cobalamin,
folate, methylmalonic acid, homocysteine, and gastritis markers in dementia. Dement Geriatr Cogn Disord, 16, 269– 275.
OKUBO, H., AKIYAMA, J., KOBAYAKAWA, M., KAWAZOE, M., MISHIMA, S., TAKASAKI, Y.,
NAGATA, N., SHIMADA, T., YOKOI, C., KOMORI, S., KIMURA, K., HISADA, Y., IWATA, E., WATANABE, K., YANAGISAWA, N., SHIROMA, S., SHIMOMURA, A., OKAHARA, K., CHO, H. & UEMURA, N. 2020. Vonoprazan- based triple therapy is eective for Helicobacter pylori eradica­tion irrespective of clarithromycin susceptibility. J Gastroenterol, 55, 1054– 1061.
OSSOWSKA, K. & LORENC- KOCI, E. 2013. Depression in Parkinson’s disease. Pharmacol Rep, 65,
1545– 1557.
 Infectious Disease and Neurocognition
PANAGIOTAKOS, D. B., PITSAVOS, C., CHRYSOHOOU, C., TSETSEKOU, E., PAPAGEORGIOU,
C., CHRISTODOULOU, G., STEFANADIS, C. & STUDY, A. 2004. Inammation, coagulation, and
depressive symptomatology in cardiovascular disease- free people; the ATTICA study. Eur Heart J,
25, 492– 499. PANDEY, R., MISRA, V., MISRA, S. P., DWIVEDI, M., KUMAR, A. & TIWARI, B. K. 2010. Helicobacter
pylori and gastric cancer. Asian Pac J Cancer Prev, 11, 583– 588. PARK, A. M., OMURA, S., FUJITA, M., SATO, F. & TSUNODA, I. 2017. Helicobacter pylori and gut
microbiota in multiple sclerosis versus Alzheimer’s disease: 10 pitfalls of microbiome studies. Clin
Exp Neuroimmunol, 8, 215– 232. PARK, J., KIM, T. J., SONG, J. H., JANG, H., KIM, J. S., KANG, S. H., KIM, H. R., HWANGBO, S.,
SHIN, H. Y., NA, D. L., SEO, S. W., KIM, H. J. & KIM, J. J. 2021. Helicobacter pylori infection is asso-
ciated with neurodegeneration in cognitively normal men. J Alzheimers Dis, 82, 1591– 1599. PAYAO, S. L. & RASMUSSEN, L. T. 2016. Helicobacter pylori and its reservoirs: A correlation with the
gastric infection. World J Gastrointest Pharmacol er, 7, 126– 132. PEDRINI, M. J., SEEWANN, A., BENNETT, K. A., WOOD, A. J., JAMES, I., BURTON, J., MARSHALL,
B. J., CARROLL, W. M. & KERMODE, A. G. 2015. Helicobacter pylori infection as a protective factor
against multiple sclerosis risk in females. J Neurol Neurosurg Psychiatry, 86, 603– 607. PIEKUT, T., HURLA, M., BANASZEK, N., SZEJN, P., DORSZEWSKA, J., KOZUBSKI, W. &
PRENDECKI, M. 2022. Infectious agents and Alzheimer’s disease. J Integr Neurosci, 21, 73. PIERANTOZZI, M., PIETROIUSTI, A., GALANTE, A., SANCESARIO, G., LUNARDI, G., FEDELE,
E., GIACOMINI, P. & STANZIONE, P. 2001. Helicobacter pylori- induced reduction of acute levo-
dopa absorption in Parkinson’s disease patients. Ann Neurol, 50, 686– 687. PRINCE, M., BRYCE, R., ALBANESE, E., WIMO, A., RIBEIRO, W. & FERRI, C. P. 2013. e global
prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement, 9, 63– 75 e2. ROKKAS, T., GISBERT, J. P., MALFERTHEINER, P., NIV, Y., GASBARRINI, A., LEJA, M., MEGRAUD,
F., O’MORAIN, C. & GRAHAM, D. Y. 2021. Comparative eectiveness of multiple dierent rst- line
treatment regimens for Helicobacter pylori infection: A network meta- analysis. Gastroenterology,
161, 495– 507.e4. ROUBAUD-BAUDRON, C., LETENNEUR, L., LANGLAIS, A., BUISSONNIERE, A., MEGRAUD, F.,
DARTIGUES, J. F., SALLES, N. & PERSONNES AGÉES QUID STUDY. 2013. Does Helicobacter
pylori infection increase incidence of dementia? e Personnes Agées QUID Study. J Am Geriatr
Soc, 61, 74– 78. ROUBAUD- BAUDRON, C., KROLAK- SALMON, P., QUADRIO, I., MEGRAUD, F. & SALLES, N.
2012. Impact of chronic Helicobacter pylori infection on Alzheimer’s disease: Preliminary results.
Neurobiol Aging, 33, 1009.e11– 19. RYU, K. H., YI, S. Y., NA, Y. J., BAIK, S. J., YOON, S. J., JUNG, H. S. & SONG, H. J. 2010. Reinfection rate
and endoscopic changes aer successful eradication of Helicobacter pylori. World J Gastroenterol,
16, 251– 255. SANTARELLI, L., GABRIELLI, M., CREMONINI, F., SANTOLIQUIDO, A., CANDELLI, M.,
NISTA, E. C., POLA, P., GASBARRINI, G. & GASBARRINI, A. 2004. Atrophic gastritis as a cause of
hyperhomocysteinaemia. Aliment Pharmacol er, 19, 107– 111. SCHULZ, J. D., HAWKES, E. L. & SHAW, C. A. 2006. Cycad toxins, Helicobacter pylori and parkin-
sonism: Cholesterol glucosides as the common denomenator. Med Hypotheses, 66, 1222– 1226. SCHWARZ, S., MORELLI, G., KUSECEK, B., MANICA, A., BALLOUX, F., OWEN, R. J., GRAHAM,
D. Y., VAN DER MERWE, S., ACHTMAN, M. & SUERBAUM, S. 2008. Horizontal versus familial
transmission of Helicobacter pylori. PLoS Pathog, 4, e1000180. SHAMIM, S. A., WARRIACH, Z. I., TARIQ, M. A., RANA, K. F. & MALIK, B. H. 2019. Insomnia: Risk
factor for neurodegenerative diseases. Cureus, 11, e6004. SHEN, S., ZHANG, C., XU, Y. M. & SHI, C. H. 2022. e role of pathogens and anti- infective agents in
Parkinson’s disease, from etiology to therapeutic implications. J Parkinsons Dis, 12, 27– 44. SHEN, X., YANG, H., WU, Y., ZHANG, D. & JIANG, H. 2017. Meta- analysis: Association of
Helicobacter pylori infection with Parkinson’s diseases. Helicobacter, 22, e12398. SHEU, B. S., SHIESH, S. C., YANG, H. B., SU, I. J., CHEN, C. Y. & LIN, X. Z. 1997. Implications of
Helicobacter pylori serological titer for the histological severity of antral gastritis. Endoscopy,
29, 27– 30.
Helicobacter pylori 161
SHIOTA, S., MURAKAMI, K., YOSHIIWA, A., YAMAMOTO, K., OHNO, S., KURODA, A.,
MIZUKAMI, K., HANADA, K., OKIMOTO, T., KODAMA, M., ABE, K., YAMAOKA, Y. & FUJIOKA, T. 2011. e relationship between Helicobacter pylori infection and Alzheimer’s disease in Japan. J Neurol, 258, 1460– 1463.
SIMANEK, A. M., ZHENG, C., YOLKEN, R., HAAN, M. & AIELLO, A. E. 2019. A longitudinal study
of the association between persistent pathogens and incident depression among older U.S. Latinos. J Gerontol A Biol Sci Med Sci, 74, 634– 641.
SOSA- ORTIZ, A. L., ACOSTA- CASTILLO, I. & PRINCE, M. J. 2012. Epidemiology of dementias and
Alzheimer’s disease. Arch Med Res, 43, 600– 608.
SZWED, P., GASECKA, A., ZAWADKA, M., EYILETEN, C., POSTULA, M., MAZUREK, T.,
SZARPAK, L. & FILIPIAK, K. J. 2021. Infections as novel risk factors of atherosclerotic cardiovas­cular diseases: Pathophysiological links and therapeutic implications. J Clin Med, 10, 2539.
TAFTI, D., EHSAN, M. & XIXIS, K. L. 2022. Multiple Sclerosis [Online]. StatPearls Publishing.
Available: https:// www.ncbi.nlm.nih.gov/ books/ NBK499 849/
TAKEOKA, A., TAYAMA, J., KOBAYASHI, M., SAGARA, I., OGAWA, S., SAIGO, T., HAYASHIDA,
M., YAMASAKI, H., FUKUDO, S. & SHIRABE, S. 2017. Psychological eects of Helicobacter pylori- associated atrophic gastritis in patients under 50 years: A cross- sectional study. Helicobacter, 22, e12445.
TAN, A. H., LIM, S. Y., MAHADEVA, S., LOKE, M. F., TAN, J. Y., ANG, B. H., CHIN, K. P.,
MOHAMMAD ADNAN, A. F., ONG, S. M. C., IBRAHIM, A. I., ZULKIFLI, N., LEE, J. K., LIM, W. T., TEO, Y. T., KOK, Y. L., NG, T. Y., TAN, A. G. S., ZULKIFLE, I. M., NG, C. K., EE, S. S., ARAFIN, S., MOHAMAD SHUKORI, K., VADIVELU, J. S., MARRAS, C., FOX, S. H. & LANG, A. E. 2020. Helicobacter pylori eradication in Parkinson’s disease: A randomized placebo- controlled trial. Mov Disord, 35, 2250– 2260.
TAN, A. H., MAHADEVA, S., MARRAS, C., THALHA, A. M., KIEW, C. K., YEAT, C. M., NG, S. W.,
ANG, S. P., CHOW, S. K., LOKE, M. F., VADIVELU, J. S., IBRAHIM, N., YONG, H. S., TAN, C. T., FOX, S. H., LANG, A. E. & LIM, S. Y. 2015. Helicobacter pylori infection is associated with worse severity of Parkinson’s disease. Parkinsonism Relat Disord, 21, 221– 225.
TSAI, C. F., CHEN, M. H., WANG, Y. P., LIU, P. Y., HOU, M. C., LEE, F. Y. & LU, C. L. 2021. Increased
risk of short- term depressive disorder aer Helicobacter pylori eradication: A population- based nested cohort study. Helicobacter, 26, e12824.
TURNER, R. S. 2003. Biomarkers of Alzheimer’s disease and mild cognitive impairment: Are we there
yet? Exp Neurol, 183, 7– 10.
VIRAMETEEKUL, S., PHOKAEWVARANGKUL, O. & BHIDAYASIRI, R. 2021. Proling the most
elderly Parkinson’s disease patients: Does age or disease duration matter? PLoS One, 16, e0261302.
WANG, B., YU, M., ZHANG, R., CHEN, S., XI, Y. & DUAN, G. 2020a. A meta- analysis of the asso-
ciation between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease. Helicobacter, 25, e12761.
WANG, H., LIU, X., TAN, C., ZHOU, W., JIANG, J., PENG, W., ZHOU, X., MO, L. & CHEN, L. 2020b.
Bacterial, viral, and fungal infection- related risk of Parkinson’s disease: Meta- analysis of cohort and case- control studies. Brain Behav, 10, e01549.
WANG, X. L., ZENG, J., FENG, J., TIAN, Y. T., LIU, Y. J., QIU, M., YAN, X., YANG, Y., XIONG, Y.,
ZHANG, Z. H., WANG, Q., WANG, J. Z. & LIU, R. 2014. Helicobacter pylori ltrate impairs spatial learning and memory in rats and increases beta- amyloid by enhancing expression of presenilin- 2. Front Aging Neurosci, 6, 66.
WANG, X. L., ZENG, J., YANG, Y., XIONG, Y., ZHANG, Z. H., QIU, M., YAN, X., SUN, X. Y.,
TUO, Q. Z., LIU, R. & WANG, J. Z. 2015. Helicobacter pylori ltrate induces Alzheimer- like tau hyperphosphorylation by activating glycogen synthase kinase- 3beta. J Alzheimers Dis, 43, 153– 165.
WHITE, A. R., HUANG, X., JOBLING, M. F., BARROW, C. J., BEYREUTHER, K., MASTERS, C.
L., BUSH, A. I. & CAPPAI, R. 2001. Homocysteine potentiates copper- and amyloid beta peptide­mediated toxicity in primary neuronal cultures: Possible risk factors in the Alzheimer’s- type neuro­degenerative pathways. J Neurochem, 76, 1509– 1520.
WORLD HEALTH ORGANIZATION. (2022). Depression and Other Common Mental Disorders:
Global Health Estimates. URL: Depression and Other Common Mental Disorders (who.int)
 Infectious Disease and Neurocognition
WU, Y., MURRAY, G. K., BYRNE, E. M., SIDORENKO, J., VISSCHER, P. M. & WRAY, N. R. 2021.
GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal dis-
orders and depression. Nat Commun, 12, 1146. WU, Y., ZHANG, L., LI, S. & ZHANG, D. 2022. Associations of dietary vitamin B1, vitamin B2, vitamin
B6, and vitamin B12 with the risk of depression: A systematic review and meta- analysis. Nutr R ev,
80, 351– 366. YAO, G., WANG, P., LUO, X. D., YU, T. M., HARRIS, R. A. & ZHANG, X. M. 2016. Meta- analysis of
association between Helicobacter pylori infection and multiple sclerosis. Neurosci Lett, 620, 1– 7. YUAN, W., BEAULIEU- JONES, B., KROLEWSKI, R., PALMER, N., VEYRAT- FOLLET, C., FRAU, F.,
COHEN, C., BOZZI, S., COGSWELL, M., KUMAR, D., COULOUVRAT, C., LEROY, B., FISCHER,
T. Z., SARDI, S. P., CHANDROSS, K. J., RUBIN, L. L., WILLS, A. M., KOHANE, I. & LIPNICK, S.
L. 2021. Accelerating diagnosis of Parkinson’s disease through risk prediction. BMC Neurol, 21, 201. YUE, L., ZHANG, R., CHEN, S. & DUAN, G. 2023. Relationship between Helicobacter pylori and in-
cident hypertension as well as blood pressure: A systematic review and meta- analysis. Dig Dis, 41,
124– 137. ZENG, M., MAO, X. H., LI, J. X., TONG, W. D., WANG, B., ZHANG, Y. J., GUO, G., ZHAO, Z. J., LI, L.,
WU, D. L., LU, D. S., TAN, Z. M., LIANG, H. Y., WU, C., LI, D. H., LUO, P., ZENG, H., ZHANG, W.
J., ZHANG, J. Y., GUO, B. T., ZHU, F. C. & ZOU, Q. M. 2015. Ecacy, safety, and immunogenicity of
an oral recombinant Helicobacter pylori vaccine in children in China: A randomised, double- blind,
placebo- controlled, phase 3 trial. Lancet, 386, 1457– 1464. ZHONG, R., CHEN, Q., ZHANG, X., LI, M. & LIN, W. 2022. Helicobacter pylori infection is associated
with a poor response to levodopa in patients with Parkinson’s disease: A systematic review and meta-
analysis. J Neurol, 269, 703– 711. ZILLI, E. M., O’DONNELL, A., SALINAS, J., APARICIO, H. J., GONZALES, M. M., JACOB, M.,
BEISER, A. & SESHADRI, S. 2021. Herpes labialis, Chlamydophila pneumoniae, Helicobacter
pylori, and Cytomegalovirus infections and risk of dementia: e Framingham Heart Study. J
Alzheimers Dis, 82, 593– 605. ZUNSZAIN, P. A., HEPGUL, N. & PARIANTE, C. M. 2013. Inammation and depression. Curr Top
Behav Neurosci, 14, 135– 151.
12
Neurocognitive Dysfunction Associated
with Tuberculous Meningitis
Sofiati Dian and Paulus Anam Ong
Introduction
In 2022, there were 10.6 million people infected with tuberculosis (TB) world­wide (World Health Organization, 2023). TB aects the central nervous system in 1– 2 percent of cases (Mezochow et al., 2017), and global data show that TB results in 12.1 disability- adjusted life- years (95 percent uncertainty interval (UI): 10.0–
14.9) lost by premature mortality and years lived with a disability for every TB case incident— 6.3 (95 percent UI: 5.6– 7.0) years were aected by the illness episode and
5.8 (95 percent UI: 3.8– 8.3) years were from aer the illness episode (Menzies et al.,
2021). In some cases, TB can result in meningitis, which aected 164,000 (95 percent UI: 129,000– 199,000) people worldwide in 2019, resulting in up to 50 percent mor­tality (Dodd et al., 2021). e British Medical Research Council classies TB menin­gitis (TBM) based on its severity: grade I TBM as a Glasgow coma score (GCS) of 15 with no focal neurology, grade II TBM as a GCS of 15 with a focal neurological def­icit or a GCS of 11– 14, and grade III TBM as a GCS of 10. TBM can further result in abnormalities in cognitive function (waites et al., 2004). Despite at least 9 months of anti- TB therapy, neurological disabilities, including cognitive impairment, motor decits, optic neuropathy, and other cranial nerve involvement, remain common in the long- term follow- up of patients with TBM (Brancusi et al., 2012; Dian et al., 2020; Li et al., 2017; M. Luo et al., 2018).
e relationship between cognitive decits and TBM can involve a focal brain le­sion, including ischemia (Dian et al., 2020; Misra et al., 2011) of the TB zone sec­ondary to vasculitis obliterans, intimal hyperplasia, a hypercoagulable state (Sy et al., 2022), tuberculoma (Chen et al., 2015; Dian et al., 2021; Garcia- Grimshaw et al., 2018), or diuse abnormalities including elevated intracranial pressure, longstanding untreated hydrocephalus (Dev et al., 2019; Shankaragouda et al., 2013), possible microvascular ischemia (Misra et al., 2011), subclinical meningoenceph­alitis, or persistent inammation leading to brain oedema (waites et al., 2000). Meanwhile, the cognitive and psychiatric functions associated with TBM have yet to be established. Some studies have reported that the cognitive abnormalities in TBM are widespread and inuence more cognitive areas than only those that can be
Sofiati Dian and Paulus Anam Ong,
and Neuropsychiatric Medicine
© Oxford University Press 2024. DOI: 10.1093/ oso/ 9780192870414.003.0013
 Infectious Disease and Neurocognition
attributed to focal structural decits alone. Further, neuroimaging ndings do not always explain the cognitive decits associated with TBM (Davis et al., 2023).
ere are some limitations in fully identifying cognitive decits in patients with TBM. First, various researchers from around the world have administered several sets of cognitive tests with dierent sensitivities and specicities in various countries and global situations. Second are variations in evaluation timing due to patients’ circumstances including anxiety or low mood (Santos et al., 2013), comorbidities (visual impairment, hearing impairment, pain, dizziness) (Nightingale et al., 2021), or fatigue. ird, there are no solid conrmatory modalities with which to correlate the anatomical lesion to cognitive impairment in people with TBM.
Clinical features and cognitive abnormalities associated with tuberculous meningitis
Despite the diculties in denitively describing the cognitive dysfunction as­sociated with TBM, cognitive impairment in TBM appears to range from 12 to
93.3 percent (Anderson et al., 2010; Davis et al., 2023; Ganaraja et al., 2021; Quinn et al., 2021), depending on the cognitive domain aected and the timing of the test. Findings from countries including Mexico, India, the United States, Africa, and New Zealand focusing on speech ability and cognitive function also have found associ­ations between TBM and cognitive function. In a very early report from Mexico, the authors found word- nding diculty associated with TBM (Booth & Curtis,
1893). Cognitive function measured within 2 weeks and at 1 year aer TBM di­agnosis in India (Ganaraja et al., 2021), at 8 and 24 weeks aer TBM diagnosis in Uganda (Quinn et al., 2021), 1 year aer TBM diagnosis in the United States in an­other early report (Hindsdale, 1901), 6 months aer TBM diagnosis in Africa (Davis et al., 2023), and 18 months aer TBM diagnosis in New Zealand (Anderson et al.,
2010) has shown a variety of abnormalities including diculty with word nding as identied by Booth and Curtis (1893), repetitive problems or conduction aphasia (Garcia- Grimshaw et al., 2018), and recent memory loss (Booth & Curtis, 1893; Shankaragouda et al., 2013). In many cases, the cognitive symptoms were not ob­viously present and became apparent only during the examination. e presenting symptom in several publications is noncognitive, including headache, loss of con­sciousness, motor abnormalities, cranial nerve palsies, or seizures (Dian et al., 2020; Imran et al., 2018; van Laarhoven et al., 2017).
Neuroanatomical abnormalities associated with TBM
TBM has been associated with decreased gray matter volume of the right thalamus, right superior temporal gyrus, right precuneus, right middle temporal gyrus, le putamen, right middle temporal gyrus (Chen et al., 2015), the arcuate fasciculus of
Tuberculous Meningitis 165
le parietal cortex (Garcia- Grimshaw et al., 2018), right caudate nucleus, and hy­pothalamus (Anderson et al., 2010) (Figure 12.1). Based on the most aected blood vessels in TBM, the lenticulostriate arteries, middle cerebral arteries, and the tha­lamic perforators (Figure 12.2), the basal ganglia, cerebral cortex, pons, and cere­bellum (Garcia- Grimshaw et al., 2018) are the areas most involved by ischemia in TBM (Chen et al., 2015). Of those areas, abnormalities of the right thalamus, le putamen, and right caudate nucleus are associated with worse cognitive function (Chen et al., 2015).
Cognitive features associated with TBM
Recent ndings have shown that the main cognitive domains aected in people with TBM who do not have human immunodeciency virus (HIV) are attention, working memory, executive function, and learning memory (Chen et al., 2015; Ganaraja et al., 2021; Quinn et al., 2021). Aer exclusion of patients with grade II and III TBM and those with imaging features of hydrocephalus, arteritis, and tuberculoma, a study in India found that learning memory and attention were the most impaired cognitive functions in TBM (Chen et al., 2015). In addition, Chen et al. also reported impairment in verbal comprehension, including general verbal skills, verbal reasoning, the ability to understand and use verbal reasoning, verbal knowledge, perceptual organization, and working memory (Chen et al., 2015). In contrast, however, Davis et al. did not nd attention and working memory decits in HIV- infected TBM (Davis et al., 2023). Although attention and working memory decits are early indicators of subcortical impairment, Davis et al. (2023) found primarily motor decits, suggesting subcortical abnormalities, so it is pos­sible that insensitive neuropsychological testing resulted in the ndings of normal attention and working memory. Further, only one tool was used in this study to assess four cognitive domains. In contrast to earlier ndings, HIV- infected TBM patients in Uganda predominantly showed decits in motor domains, processing speed, verbal learning, and executive function (Quinn et al., 2021). In compar­ison, cognitive decits in other infectious diseases, such as from Covid- 19, pri­marily aect executive function, episodic and working memory, and attention. Psychiatric impairment, including anxiety and depression, also can be present (Serrano- Castro et al., 2022). is pattern of cognitive decits may be dierent from the pattern of cognitive decits typically found in Alzheimer’s disease, that is, memory (Jalbert et al., 2008), as attributed to the entorhinal cortex, hippocampus, parietal lobe, isthmus of the cingulate gyrus, the temporal lobe, amygdala, tem­poral pole, corpus callosum, nucleus accumbens, and parahippocampal atrophy (Pölsterl et al., 2023).
Postcentral gyrus
fusiform gyrus
Prefronta
Precentral gyrus
Cingulate gyrus
Precuneus
Insula
Thalamus
nucleus
Right caudate
Right superior
temporal gyrus
Claustrum
Le putamen and
nucleus
Red nucleus
Subthalamic
Right middle
globus pallidus
Parahippocampal and
Pons
Hippocampus
temporal gyrus
Parietal
Wernicke
l
cortex
Figure 12.1 Tuberculous meningitis has been associated with decreased gray matter volume of the right thalamus, right superior temporal gyrus, right
precuneus, right middle temporal gyrus, le putamen, right middle temporal gyrus (Chen et al., 2015), right caudate nucleus, and hypothalamus (Anderson
et al., 2010).
Source: Created with BioRender.com.
Tuberculous Meningitis 167
Thalamo-
al a.
Internal carotid a.
perforating branches
Striate branches of middle cerebral a.
Middle cerebral a.
Posterior communicating a.
Figure 12.2 The most commonly aected vessels in TBM are the lenticulostriate arteries, middle cerebral arteries, and thalamic perforate at tuberculosis zone secondary to vasculitis obliterans, intimal hyperplasia, a hypercoagulable state.
Source: Created with BioRender.com.
Thalamus
Posterior cerebr
Attention
e pathophysiology of attention impairment in TBM is not fully understood. e involvement of brain areas responsible for attention processing has been reported by Chen et al. (2015). e smaller gray matter volume mainly aected the suitable hem­isphere structures, such as the right thalamus and right superior temporal gyrus, in TBM patients compared to controls, suggesting the disruption of subsystems of orienting, attention selection (ignoring distractibility), and maintaining vigilance in TBM patients (Chen et al., 2015).
William James, in 1890, dened attention as the mind’s possession of multiple
simultaneous objects or trains of thought in clear and vivid form (Fan & Posner,
2004). A testable model of attention processing proposed by Posner and Petersen (1990) is crucial to understanding normal and disturbed attention. e attention system has three subsystems: orienting, detecting, and alerting/ vigilance. Orienting refers to sensory processes such as visual foveation of a stimulus, which relies on the parietal cortex, superior colliculus, and pulvinar/ thalamus. e detection subsystem detects targets that would undergo further information process using the anterior cingulate cortex and lateral prefrontal cortex, while the alerting system maintains general vigilance through the noradrenergic locus coeruleus inuences mainly on the right hemisphere structures (Posner & Petersen, 1990).
A recent study using whole- brain functional magnetic resonance imaging (MRI),
diusion- weighted MRI, and whole- brain tractography found that the concentration